These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 898127)

  • 21. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.
    Rangno RE; Warnica W; Ogilvie RI; Kreeft J; Bridger E
    J Int Med Res; 1976; 4(1 Suppl):54-8. PubMed ID: 1026530
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide].
    Witkowska M
    Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612
    [No Abstract]   [Full Text] [Related]  

  • 23. Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets.
    Graffner C; Lagerström PO; Lundborg PN; Rönn OF
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):414-9. PubMed ID: 7298249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
    Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
    Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous and oral disopyramide after myocardial infarction.
    Nicholls DP; Haybyrne T; Barnes PC
    Lancet; 1980 Nov; 2(8201):936-8. PubMed ID: 6107587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral disopyramide dosage regimes in ischaemic heart disease.
    Bryson SM; Fotheringham GH; Struthers MG; Whiting B
    J Clin Hosp Pharm; 1982 Mar; 7(1):37-42. PubMed ID: 7096577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disopyramide pharmacokinetics during recovery from myocardial infarction.
    Bryson SM; Cairns CJ; Whiting B
    Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placental and milk transfer of disopyramide and metabolites.
    Karim A; Kook C; Campion J
    Drug Metab Dispos; 1978; 6(3):346-8. PubMed ID: 26557
    [No Abstract]   [Full Text] [Related]  

  • 31. Disopyramide dialysability.
    Lancet; 1978 Jul; 2(8082):214. PubMed ID: 78419
    [No Abstract]   [Full Text] [Related]  

  • 32. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.
    Hinderling PH; Garrett ER
    J Pharmacokinet Biopharm; 1976 Jun; 4(3):199-230. PubMed ID: 978389
    [No Abstract]   [Full Text] [Related]  

  • 34. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 37. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bioavailability of procainamide and disopyramide with and without concomitant administration of an antacid: aluminium phosphate (author's transl)].
    Albin H; Vinçon G; Bertolaso D; Dangoumau J
    Therapie; 1981; 36(5):541-6. PubMed ID: 7323992
    [No Abstract]   [Full Text] [Related]  

  • 39. [Evaluation of the efficacy of anti-arrhythmia agents in hyperkinetic ventricular arrhythmia].
    Bracchetti D; Mantovani B; Naccarella F; Lombardi G; Palmieri M
    Boll Soc Ital Cardiol; 1980; Suppl():117-23. PubMed ID: 7349604
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of intravenous disopyramide in supraventricular paroxysmal tachycardia refractory to vagal maneuvers].
    Romero-Ayala LC; Soní J
    Arch Inst Cardiol Mex; 1983; 53(2):147-51. PubMed ID: 6882095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.